Have you evaluated the performance of Haemonetics' (HAE Quick QuoteHAE - Free Report) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of this provider blood management systems for health care providers and blood collectors, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

Upon examining HAE's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

The company's total revenue for the quarter amounted to $327.32 million, marking a decrease of 5.3% from the year-ago quarter. We will next turn our attention to dissecting HAE's international revenue to get a clearer picture of how significant its operations are outside its main base.

Unveiling Trends in HAE's International Revenues

Japan generated $18.01 million in revenues for the company in the last quarter, constituting 5.5% of the total. This represented a surprise of +2.63% compared to the $17.55 million projected by Wall Street analysts. Comparatively, in the previous quarter, Japan accounted for $13.65 million (4.3%), and in the year-ago quarter, it contributed $16.42 million (4.8%) to the total revenue.

Europe accounted for 13.1% of the company's total revenue during the quarter, translating to $42.97 million. Revenues from this region represented a surprise of -2.89%, with Wall Street analysts collectively expecting $44.25 million. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $40.88 million (12.7%) and $41.99 million (12.2%) to the total revenue, respectively.

Of the total revenue, $3.68 million came from Other International during the last fiscal quarter, accounting for 1.1%. This represented a surprise of +43.31% as analysts had expected the region to contribute $2.57 million to the total revenue. In comparison, the region contributed $2.81 million, or 0.9%, and $5.27 million, or 1.5%, to total revenue in the previous and year-ago quarters, respectively.

International Revenue Predictions

It is projected by analysts on Wall Street that Haemonetics will post revenues of $333.6 million for the ongoing fiscal quarter, a decline of 4.3% from the year-ago quarter. The expected contributions from Japan, Europe and Other International to this revenue are 5.3%, 13.5%, and 0.7%, translating into $17.74 million, $45.12 million, and $2.31 million, respectively.

For the entire year, the company's total revenue is forecasted to be $1.31 billion, which is a reduction of 4% from the previous year. The revenue contributions from different regions are expected as follows: Japan will contribute 5.2% ($67.82 million), Europe 13.3% ($174.14 million) and Other International 0.9% ($11.29 million) to the total revenue.

Key Takeaways

Haemonetics' leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.

At the moment, Haemonetics has a Zacks Rank #3 (Hold), signifying that its performance may align with the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Haemonetics' Recent Stock Market Performance

Over the preceding four weeks, the stock's value has appreciated by 46.2%, against an upturn of 1.5% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Haemonetics among its entities, has appreciated by 5.3%. Over the past three months, the company's shares have seen an increase of 30.4% versus the S&P 500's 4.5% increase. The sector overall has witnessed an increase of 10% over the same period.